Abstract Body

Background: Convenient dosing, potency, and low toxicity profile support use of tenofovir disoproxil fumarate (TDF) as the preferred first line nucleotide reverse transcriptase inhibitor (NRTI) in combination regimens for HIV-1 treatment. However, renal and metabolic safety of TDF compared to other NRTI in resource-limited settings has not been well described. Methodology: Secondary analysis within the ACTG A5175/PEARLS trial, examining the renal and metabolic safety outcomes between participants randomized to zidovudine/lamivudine plus efavirenz (ZDV/3TC + EFV) and TDF/emtricitabine plus EFV treatment arms. Adverse event analysis included occurrence of renal abnormalities (Grade ≥ 3 serum creatinine levels or calculated creatinine clearance [CrCl] by Crockoft-Gault method < 50 ml/min), renal and metabolic serious non-AIDS defining events (SNADEs) at study follow up. Logistic regression explored association between baseline covariates and renal abnormalities. Wilcoxon tests compared serum creatinine with urine dipstick results every 24 weeks and response profiles analysis for CrCl levels over time. Results: Twenty-one of 1045 participants developed renal abnormalities through 192 weeks (Table 1); 71% were in TDF arm (p=0.08). History of diabetes (OR: 10.7, 95% CI: 2.2-52.1), history of AIDS event (OR: 2.7, 95%CI: 0.95-57.4) and a lower baseline CrCl (OR: 3.1 per each 25 ml/min decline, 95% CI: 1.8-6.1) were each associated with development of renal abnormalities. Renal SNADEs occurred in 4% of patients, the majority were urinary tract infections (79%). Renal failure was recorded in 4/42 patients with renal SNADEs and only one event was attributed to TDF use. Serum creatinine levels did not significantly differ to urine dipstick results (normal versus abnormal) at any time point. Significantly lower CrCl values were observed in patients receiving TDF compared to ZDV, but magnitude of difference was small (medians ranging from 98 vs. 106 ml/min at 24 weeks; p < 0.001, to 103 vs. 106 ml/min at 96 weeks; p=0.07, repeated measures analysis from baseline p=0.05). Serious metabolic diagnoses were rare but higher in the ZDV arm (3 vs. 20 cases; p< 0.001). Conclusions: TDF use was not associated with a significant risk of renal abnormalities or serious renal events compared to ZDV in this randomized, multinational study. However, slightly larger declines in CrCl, of unknown clinical importance, were observed with TDF use over time.